InvestSMART

Osteopore Limited (ASX: OSX) - Share Price

Current share price for OSX : $0.005 0.001 (10%)+

Osteopore Limited (OSX), an ASX-listed company, is a global medical technology Company that commercialises products designed to enable natural bone healing across multiple therapeutic areas. The Company's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

OSX General Information +

ASX Code OSX
Website http://www.osteopore.com
Industry/Sector Health Care Supplies
Market Cap ($M) 3
OSX Share Price $0.005
Day High $0.005
Day Low $0.005
Last Close $0.005
OSX Share Price Movement $0.00 ( 10% )
Prices as at 16:40, 9 Jul 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Osteopore Limited (OSX) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from Osteopore Limited (OSX) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Osteopore Limited (OSX) price-sensitive announcements

OSX - Further Drawdown of T2 of the Redeemable Convertible Notes
Osteopore Limited, a leader in 3D-printed biomimetic and bioresorbable implants, announced
Osteopore Limited (OSX)
23 Jun 2026 | 8:51 AM
OSX - OSX secures Hainan FDA approval for orthopaedic devices
Osteopore Limited, an Australian-Singaporean regenerative medicine company, has received a
Osteopore Limited (OSX)
26 May 2026 | 8:59 AM
OSX - Activities Report March 2026 and Appendix 4C
Osteopore Limited's quarterly report for Q1 2026 highlighted a revenue growth of 10% quart
Osteopore Limited (OSX)
30 Apr 2026 | 8:32 AM
OSX - Further Drawdown of T2 of the Redeemable Convertible Notes
Osteopore Limited, a Singapore-founded regenerative medicine company specializing in 3D-pr
Osteopore Limited (OSX)
26 Mar 2026 | 6:35 PM

Osteopore Limited (OSX) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
Osteopore Limited (OSX)
ORDINARY FULLY PAID
 Health Care $3 OSX & Zimmer gain craniofacial market access to Saudi Arabia 7 Jul 2026 8:34AM $0.005 $0.005 fallen by 10%
Osteopore Limited (OSX)
ORDINARY FULLY PAID
 Health Care $3 OSX completes co-development project for neurosurgical guide 2 Jul 2026 8:24AM $0.005 $0.005 fallen by 10%
Osteopore Limited (OSX)
ORDINARY FULLY PAID
 Health Care $3 First patient treated in OSX-PAH jaw reconstruction trial 30 Jun 2026 8:52AM $0.004 $0.005 risen by 12.50%
Osteopore Limited (OSX)
ORDINARY FULLY PAID
 Health Care $3 First 2 patients treated in QCH cleft lip clinical trial 29 Jun 2026 8:26AM $0.005 $0.005 fallen by 0%
Osteopore Limited (OSX)
ORDINARY FULLY PAID
 Health Care $3 QCH cleft lip clinical study patient recruitment completed 26 Jun 2026 8:17AM $0.004 $0.005 risen by 12.50%
Osteopore Limited (OSX)
ORDINARY FULLY PAID
 Health Care $3 OSX neuro products approved in a major centre in Thailand 24 Jun 2026 8:52AM $0.005 $0.005 fallen by 0%

OSX Financial Summary

Year to Dec NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2025A -$3.63 -$1.90 -54.90% 0.00 0.00 0.00% 0.0%
2024A -$3.35 -$4.30 -49.20% 0.00 0.00 0.00% 0.0%
2023A -$4.87 -$8.40 -6.20% 0.00 0.00 0.00% 0.0%

OSX Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2023 A 2024 A 2025 A 2023 A 2024 A 2025 A 2023 A 2024 A 2025 A
Ansell Limited (ANN) $4,482M 0.2270 0.0582 0.1434 16.6937 15.7752 13.7964 2.40% 2.87% 3.28%
Nanosonics Limited (NAN) $1,007M 0.5929 0.0000 0.0000 50.3737 0.0000 0.0000 0.00% 0.00% 0.00%
Osteopore Limited (OSX) $3M -0.5491 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Polynovo Limited (PNV) $691M 1.5200 0.0000 0.0000 52.9101 0.0000 0.0000 0.00% 0.00% 0.00%

OSX Market Comparison

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 -0.79 0.00
Market 0.28 13.00 1.14 0.58
Sector 0.68 23.20 1.59 2.54

OSX Directors

Name Position Start Date
Dr Yujing Lim Chief Executive Officer, Executive Director 24 Sep 2024
Mr Mark Kei Wei Leong Executive Chairman, Executive Director 1 Aug 2021
Professor Swee Hin Teoh Non-Executive Director 24 Jun 2019
Hon Michael Keenan Non-Executive Director 18 Jul 2023

Osteopore Limited (OSX) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
8 May 2024 LEONG, Mark Issued Direct Shares 125,000 $0.029 $3,625.000
8 May 2024 TEOH, Swee Hin Issued Indirect Shares 584,897 $0.029 $16,962.000
4 Jul 2023 LEONG, Mark Sell Direct Shares 162,500 $0.083 $13,501.800

See all changes in directors' interest & trades for Osteopore Limited (OSX) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

OSX Management

Name Position
Jack Rosagro Company Secretary

OSX Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Osteopore Limited (OSX). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
89,196,511 (15.86%) Citicorp Nominees Pty Ltd
70,739,752 (12.58%) BNP Paribas Nominees Pty Ltd

OSX Calendar of Events

Date Event
30 March 2027 Report (Annual)
26 February 2027 Report (Prelim)
28 August 2026 Report (Interim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.